Previous 10 | Next 10 |
John Paulson’s, Paulson & Co. raised its positions in Perpetua Resources (NASDAQ:PPTA) to ~24.77M shares from ~20.94M and DiDi Global (NYSE:DIDI) to ~12.7M shares from ~11.08M in its latest 13F filing taking the total table value to $3.5...
An Appeals court upheld a trial judge’s ruling to dismiss a patent claimed by Horizon Therapeutics (HZNP -1.6%) for rheumatoid arthritis therapy Duexis, Bloomberg reports U.S. Court of Appeals for the Federal Circuit also ruled that Indian pharma company, Alkem had not infrin...
– Campaign helps people know their risks and identify the signs and symptoms of TED to encourage early diagnosis and management – Horizon Therapeutics plc (Nasdaq: HZNP) today announced its support of Thyroid Eye Disease (TED) Awareness Week through the lau...
-- Analysis to be presented during AAO 2021 demonstrates 90% of patients finished full course of TEPEZZA therapy (eight infusions), indicating strong patient adherence -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced findings of a real-world adherence analysis of T...
Horizon Therapeutics (NASDAQ:HZNP) announces that the EMA's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for UPLIZNA (inebilizumab) as a monotherapy for the treatment of certain adult patients with neuromyelitis...
-- CHMP recommendation based on positive results from N-MOmentum, the largest clinical trial ever conducted in NMOSD to date -- -- In the trial, UPLIZNA was shown to reduce the risk of relapse by 77% compared to placebo in anti-aquaporin-4 antibody positive (AQP4-IgG+)...
Horizon handily beat Q3 estimates and raised the full-year guidance. The beat was not enough to push the stock to new highs as investors seem accustomed to blowout quarters. But not every quarter can be a blowout quarter. Uplizna re-launch is underway while Duexis is facing generi...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2b pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 (LPAR 1 ) antagonist to treat people with diffuse cutaneous systemic sclerosis, a...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the Chicago Tribune’s Top Workplaces 2021 , ranking No. 5 out of 75 other midsize companies in the Chicago area. This is Horizon’s seventh time on the list. “We are always ...
-- Complete data from PROTECT trial shows 89% of patients achieved the primary endpoint -- -- Additional presentations call attention to the high prevalence of gout and its associated comorbidities among individuals undergoing dialysis -- Horizon Therapeutics plc (Na...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...